Proactive Investors - Run By Investors For Investors

ANGLE device offers breakthrough in prostate cancer care

The team at the Bart's Cancer Institute at Queen Mary University will present their full findings at the National Cancer Research Institute next week.
ANGLE device offers breakthrough in prostate cancer care
The company's Parsortix device offers a non-invasive means of detecting prostate cancer.

ANGLE PLC (LON:AGL, OTCQX:ANPCY) has welcomed new research that potentially supports the use of the company’s breakthrough cancer detection system as an alternative to biopsies in men with suspected prostate cancer.

The team at the Bart's Cancer Institute at Queen Mary University will present their full findings at the National Cancer Research Institute next week.

What they found was ANGLE’s Parsortix device was able to capture a very specific subset of circulating tumour cells from prostate cancer patient blood samples.

These cells, which cannot be captured by traditional systems, are linked to the spread of the disease.

It means Parsortix could potentially be used gauge at what stage and how severe the prostate cancer is.

Andrew Newland, chief executive and the med-tech company’s founder, said: "This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue.”

Currently the removal of tissue is standard for men with suspected prostate cancer - yet 75% to 80% of them do not have the disease. It means they risk serious complications.

“Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients,” said Newland. 

“We look forward to our continued work with Barts to progress the use of Parsortix in prostate cancer."

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use